Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.70 |
| ▸ | DHFR | P00374 | 3/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | HEXA | P06865 | 1/20 | 0.47 |
| ▸ | HEXB | P07686 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734162 | 0.82 | PTPN1 (1.00) | PTPN1NLRP3 | |
| SCHEMBL4380079 | 0.79 | PTPN1 (0.74) | PTPN1HEXAHEXBNLRP3 | |
| SCHEMBL13040779 | 0.78 | NLRP3 (0.61) | DHFRADORA2ANLRP3DCPSMTOR | |
| Trifluoroacetic Acid SCHEMBL3742964 | 0.73 | PTPN1 (0.67) | PTPN1NLRP3 | |
| SCHEMBL8813941 | 0.73 | PIK3CG (0.54) | PTPN1DHFRADORA2AHEXAHEXB | |
| SCHEMBL14520719 | 0.72 | ADORA1 (0.49) | DHFRADORA2ADCPS | |
| SCHEMBL4516307 | 0.71 | DHFR (0.73) | DHFRADORA2ADCPS | |
| SCHEMBL16716061 | 0.70 | IDO1 (0.46) | PTPN1HEXAHEXB | |
| SCHEMBL11377936 | 0.69 | DHFR (0.49) | PTPN1DHFRADORA2AHEXAHEXB | |
| SCHEMBL10456495 | 0.69 | MTOR (0.62) | PTPN1DHFRADORA2AHEXAHEXB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280021-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2010-11-04 | — | — | US | disclosed |
| US-20100280021-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2010-11-04 | — | — | US | disclosed |
| US-20100280021-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2010-11-04 | — | — | US | disclosed |
| EP-1910359-B1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | disclosed |
| EP-1910359-B1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-20090062276-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2009-03-05 | — | — | US | disclosed |
| US-20090062276-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2009-03-05 | — | — | US | disclosed |
| US-20090062276-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | BERTHEL STEVEN JOSEPH | 2009-03-05 | — | — | US | disclosed |
| EP-1910359-A1 | PYRIDO [2 , 3-D]PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | F. Hoffmann-Roche AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009911-A1 | PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009911-A1 | PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021445-A1 | Pyridopyrimidine protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-01-25 | — | — | US | disclosed |
| US-20070021445-A1 | Pyridopyrimidine protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-01-25 | — | — | US | disclosed |
| US-20070021445-A1 | Pyridopyrimidine protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062276-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PTPRF, PTPN1, PTPRCAP | PTPN1 2/4885DHFR 522/4885ADORA2A 1864/4885 |
| US-20070021445-A1 | Pyridopyrimidine protein tyrosine phosphatase inhibitors | PTPRF, PTPN1, PTPRCAP | PTPN1 2/4885DHFR 522/4885ADORA2A 1864/4885 |
| US-20100280021-A1 | PYRIDOPYRIMIDINE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PTPRF, PTPN1, PTPRCAP | PTPN1 2/4885DHFR 522/4885ADORA2A 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.